rhEPO治疗非小细胞肺癌伴贫血的效果观察

Effects of rhEPO in treatment of NSCLC with anemia

目的观察促红细胞生成素对非小细胞肺癌合并贫血的治疗效果。方法收集60例合并轻中度贫血的非小细胞肺癌患者,随机分为试验组和对照组,各30例。所有患者均按既定方案继续进行肺癌化疗,试验组同时予促红细胞生成素(rhEPO)治疗,而对照组不予rhEPO治疗。两组均每周记录治疗期间血红蛋白(Hb)水平,治疗开始前和结束后,分别评价两组一般身体状况和生活质量;治疗结束后,评价两组治疗效果。结果治疗8 w后,试验组Hb水平明显提高,且显著高于对照组(P<0.05),而对照组Hb水平则无明显改善;治疗结束后,试验组一般身体状况和生活质量改善者构成比均显著大于对照组(P<0.05)。在肿瘤治疗效果上,两组没有明显差别(P>0.05)。结论 rhEPO能明显改善非小细胞肺癌患者的贫血情况,改善患者身体的一般情况和生活质量,提高患者对治疗的耐受力,可能有助于改善患者远期预后。

Objective To observe the effects of rhEPO in the treatment of nonsmall-cell lung cancer （NSCLC） with anemia. Methods A total of 60 patients with NSCLC and mild to moderate anemia were selected and randomly divided into an experiment group and a control group （n=30, respectively）. All patients received lung cancer chemotherapy in accordance with the established plan. In addition, the experiment group was treated with rhEPO while the control group was not. The levels of Hb during the treatment in the two groups were recorded weekly. The general physical condition and quality of life in the two groups were evaluated respectively before and after the treatment; at the end of the treatment, the effects in the two groups were evaluated. Results Eight weeks later, the Hb levels in the experiment group increased greatly and was significantly higher than that in the control group （P 〈 0.05）, while that in the control group had no obvious change; after the treatment, the ratio of patients whose general physical condition and quality of life were improved in the experiment group was significantly greater than that in the control group（P 〈 0.05）. There was no significant difference in the effects on NSCLC between the two groups（P 〉 0.05）. Conclusion rhEPO can significantly improve the anemia of patients with NSCLC, their general physical conditions and quality of life, and their tolerance for treatment; it is maybe helpful for improving the long-term prognosis of patients, which needs further study and confirmation.